Evonile Pharma's Q2 FY27 revenue fell to Rs 56 crore as the company pivots from a single-customer model to an independent operation. The quarter was impacted by Rs 83 crore in one-time transition and exit costs, including the acquisition of Pfizer's cardiology brand, Minipress XL. Management is focusing on building a 900-member field force and targeting a return to operational stability by Q4 FY27.
Evonile Pharma Navigates Business Restructuring in Q2 FY27
Revenue dropped to INR 56 crore from INR 90 crore in the year-ago period.
Adjusted Operating EBITDA stood at a loss of INR 16 crore for the quarter.
Reader Takeaway: The company is absorbing high one-time transition costs to gain independence, eyeing recovery by Q4 FY27.
What just happened
Evonile Pharma has released its Q2 FY27 results, showing the significant financial friction of transforming from a single-customer reliant model to an independent pharmaceutical player. Revenue for the quarter was INR 56 crore, significantly down from the INR 90 crore reported in Q2 FY26. The bottom line was pressured by INR 83 crore in one-time expenses, comprising INR 68 crore in exceptional items related to the termination of legacy customer arrangements and INR 15 crore in transition and acquisition costs.
Why this matters
The company is aggressively building its own infrastructure. It has onboarded over 20 CFAs to secure a nationwide supply chain and is currently hiring a 900-member medical representative team. Crucially, the company has acquired the cardiology brand Minipress XL from Pfizer, a product with a dominant 50% market share, to diversify its revenue stream. It also secured distribution rights for retina portfolio drugs, Accentrix and Pagenax.
The backstory
Historically, the firm operated under a single-customer model, which accounted for a large portion of its previous revenue base. The shift to an independent setup is designed to unlock long-term growth and margin control but requires heavy upfront investment in systems—such as new accounting and HR platforms—and field force expansion.
Risks to watch
Investors should closely track the execution risk associated with the recruitment of 900 medical representatives. If deployment lags, the company may struggle to maintain market share. Additionally, the company expects another INR 15 crore to INR 20 crore in transition costs during Q3, which will continue to impact short-term profitability.
What to track next
The primary monitorable is the timeline for reaching operational breakeven, currently projected for Q4 FY27 or Q1 FY28. Furthermore, investors should watch for the planned debt reduction measures, which may include a potential rights issue before the fiscal year ends on March 31, 2027.